Resolution of acyclovir-associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature

被引:17
作者
Watson, W. A. [1 ]
Rhodes, N. J. [1 ,2 ]
Echenique, I. A. [3 ]
Angarone, M. P. [4 ]
Scheetz, M. H. [1 ,2 ]
机构
[1] Northwestern Mem Hosp, Dept Pharm, Chicago, IL USA
[2] Midwestern Univ, Chicago Coll Pharm, Dept Pharm Practice, Downers Grove, IL 60515 USA
[3] Cleveland Clin Florida, Dept Infect Dis, Weston, FL USA
[4] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
acyclovir; adverse effects; pharmacodynamics; pharmacokinetics; statistical model; RENAL-FAILURE; CLINICAL-EXPERIENCE; PHARMACOKINETICS; VALACICLOVIR; VALACYCLOVIR; SYMPTOMS; PATIENT; HUMANS;
D O I
10.1111/jcpt.12520
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
What is known and objectiveNeurotoxicity is a side effect of acyclovir. We report the first case, to our knowledge, whereby Bayesian-informed clearance estimates supported a therapeutic intervention for acyclovir-associated neurotoxicity. Case summaryA 62-year-old male with the diagnosis of disseminated zoster was being treated with intravenous (IV) acyclovir when he developed symptoms of acute neurotoxicity. Acyclovir had been dose-adjusted for renal dysfunction according to traditional creatinine clearance estimates; however, as the patient was also on vancomycin, Bayesian estimates of vancomycin clearances were performed, which revealed a 2-fold lower creatinine clearance. In response to the Bayesian estimates, acyclovir was discontinued, and improvements in mentation were noted within 24hours. What is new and conclusionAlternate approaches to estimate renal function beyond Cockcroft-Gault, such as a Bayesian approach used in our patient, should be considered when population estimates are likely to be inaccurate and potentially dangerous to the patient.
引用
收藏
页码:350 / 355
页数:6
相关论文
共 26 条
  • [1] ACYCLOVIR NEUROTOXICITY - CLINICAL-EXPERIENCE AND REVIEW OF THE LITERATURE
    ADAIR, JC
    GOLD, M
    BOND, RE
    [J]. SOUTHERN MEDICAL JOURNAL, 1994, 87 (12) : 1227 - 1231
  • [2] Almond MK, 2003, NEPHROL DIAL TRANSPL, V18, P2680, DOI 10.1093/ndt/gfg466
  • [3] [Anonymous], 2003, BASIC CLIN PHARMACOK
  • [4] Aoki FY, 2010, MANDELL DOUGLAS BENN
  • [5] Valacyclovir neurotoxicity: clinical experience and review of the literature
    Asahi, T.
    Tsutsui, M.
    Wakasugi, M.
    Tange, D.
    Takahashi, C.
    Tokui, K.
    Okazawa, S.
    Okudera, H.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (04) : 457 - 460
  • [6] Astellas Pharma US. Inc, 2015, PROGR TACR CAPS USP
  • [7] Bedford Laboratories, 2013, AC INJ USP PACK INS
  • [8] Reversible brain MRI changes in acyclovir neurotoxicity
    Blohm, MEG
    Nurnberger, W
    Aulich, A
    Engelbrecht, V
    Burdach, S
    [J]. BONE MARROW TRANSPLANTATION, 1997, 19 (10) : 1049 - 1051
  • [9] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [10] desKnegt RJ, 1995, NEPHROL DIAL TRANSPL, V10, P1775